Is Edwards Lifesciences (EW) Undervalued As TAVR And EVOQUE Growth Hopes Build?

Recent share price performance and business snapshot

Edwards Lifesciences (EW) stock has moved quietly higher, with the share price at US$90.75 as of the most recent close, and positive total returns over the past year and past 3 months.

The company reports annual revenue of US$6.5b and net income of US$979.9m, mainly from medical products that treat advanced cardiovascular diseases. Operations span the United States, Europe, Japan and other international markets.

Over the past month the stock shows a gain of about 5%, with a year to date return above 6%. The 1 year total return is just over 11%, while the 5 year total return reflects a decline.

For you as an investor, the key takeaway is that Edwards Lifesciences combines a recent 30 day share price return of 5.44% and a year to date share price return of 6.35% with a 1 year total shareholder return of 11.57%, while the 5 year total shareholder return shows a decline of about 25%. This points to improving short term momentum against a weaker longer term record.

Compare Edwards Lifesciences' recent momentum with a hand picked 45 high quality undervalued stocks that combine solid balance sheets with cash flows the market may be underrating.

Edwards Lifesciences has bounced in the short term while the 5 year record still shows a decline. Should you lean into the recent strength now or wait for a clearer margin of safety on valuation?

Most Popular Narrative: 10.1% Undervalued

On the most followed view of Edwards Lifesciences, a fair value of about $100.96 compares with the current $90.75 share price. This points to a modest valuation gap that rests heavily on future growth in its structural heart franchise.

The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future. The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.

Read the complete narrative.

Want to see what sits behind that confidence in Edwards Lifesciences? The narrative leans on faster earnings growth, wider margins, and a richer future profit multiple than the sector. Curious which specific financial milestones this view needs to line up for that fair value to hold?

Result: Fair Value of $100.96 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Edwards Lifesciences still faces tariff and acquisition related cost pressures, along with rising R&D and competitive headwinds that could challenge the current undervalued narrative.

Find out about the key risks to this Edwards Lifesciences narrative.

Another view on Edwards Lifesciences valuation

The analyst narrative frames Edwards Lifesciences as about 10.1% undervalued, yet the current 53.4x P/E is far higher than the 27.5x US Medical Equipment industry average and the 27.8x peer average. It also sits above a fair ratio of 34.7x, which points to meaningful valuation risk if expectations slip.

For context on how the current P/E compares in detail, and what that gap to the fair ratio could imply if sentiment cools, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed tone around Edwards Lifesciences, with both concerns and bright spots in focus, it may be useful to review the numbers yourself and move promptly to an informed view that reflects your own risk tolerance and return expectations by weighing the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Edwards Lifesciences?

If you are serious about building a stronger portfolio, use the Simply Wall Street Screener to uncover opportunities that match your goals before the crowd notices.

• Target potential mispricing by scanning a 45 high quality undervalued stocks where quality fundamentals may not yet be fully reflected in market prices.
• Strengthen your defensive side by reviewing a list of solid balance sheet and fundamentals (52 results) that can help support resilience when conditions become more challenging.
• Hunt for future leaders early by checking a 19 high quality undiscovered gems that combines quality metrics with lower current market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com